Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
A. D‘Urzo, E. Kerwin, J. Donohue, S. Rennard, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Toronto, Canada; Medford, Chapel Hill, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain)
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Session: Trials in COPD: novel treatments and insights
Session type: Poster Discussion
Number: 2890
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. D‘Urzo, E. Kerwin, J. Donohue, S. Rennard, A. Gelb, H. Lakkis, E. Garcia Gil, C. Caracta (Toronto, Canada; Medford, Chapel Hill, Omaha, Lakewood, Jersey City, United States Of America; Barcelona, Spain). Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I. Eur Respir J 2012; 40: Suppl. 56, 2890
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007
Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment Source: Eur Respir J 2006; 28: Suppl. 50, 199s Year: 2006
Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Tiotropium bromide: Efficacy and safety in complex treatment of COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001
Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004
ACCORD COPD I: Improvements in nighttime symptoms and rescue medication use in COPD with twice-daily aclidinium bromide Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011